To view this video, please enable marketing cookies from Cookie Preferences in the footer.
In this lecture from This is Why, Dr. Busti will explain the COPD maintenance inhalers you’ll actually see in practice. In this pharmacology review, we break down LAMA (long-acting muscarinic antagonist) bronchodilators—one of the most important bronchodilator classes for COPD treatment—so you can confidently understand the drugs, the mechanism, and the real-world clinical use.
You’ll learn how to:
- What LAMA / antimuscarinic bronchodilators are and how they work
- Where LAMA inhalers fit in COPD therapy and long-term symptom control
- Key differences and practical pearls for common COPD inhalers
- High-yield side effects, contraindications, and patient counseling points
- How to recognize and avoid common med errors and confusion with inhaler names/classes
Drugs covered:
- Tiotropium (Spiriva)
- Umeclidinium (Incruse Ellipta)
- Aclidinium (Tudorza Pressair)
- Glycopyrrolate (COPD maintenance formulations)
The goal = make medical education easy and clinically relevant.
Chapter Table of Contents
00:00 - Introduction to Long-Acting Muscarinic Antagonists
01:33 - Agents
02:14 - Indications & Uses
05:22 - Net Benefit
06:15 - Pharmacology
13:56 - Clinical Knowledge
23:55 - Summary
If this helped you, please like, subscribe to our YouTube Channel, and share it with a classmate or colleague. That will help this new channel continue producing free, high-yield medical education content.
Don’t forget to turn on notifications on YouTube so you don’t miss upcoming lectures in pharmacology, medical rounds, and more!
#lama #copd #tiotropium #umeclidinium #busti
Disclaimer:
This content is for educational purposes only and is not medical advice. It does not replace individualized evaluation, diagnosis, or treatment. Always seek the advice of a qualified health provider with questions about a medical condition and never delay care because of educational content.
More than just access—it’s where understanding deepens.
Create a free account or log in to gain access to this content!
Related Topics
